Renaissance Capital logo

Sana Biotechnology Priced, Nasdaq: SANA

Preclinical biotech developing engineered cell therapies for multiple indications.

Industry: Health Care

Latest Trade: $25.88 0.00 (0.0%)

First Day Return: +40.4%

Return from IPO: +3.5%

Industry: Health Care

We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologics to clinical practice. Our long-term aspirations are to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access to cellular and gene-based medicines. We have brought together an experienced group of scientists, engineers, and company builders and combined them with the necessary technologies to move this vision forward. We are developing in vivo and ex vivo cell engineering platforms to revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. While our current product candidates are all in preclinical development, our goal is to file multiple investigational new drug applications (INDs) both in 2022 and 2023.
more less
IPO News for Sana Biotechnology
more
IPO Data
IPO File Date 01/13/2021
Offer Price $25.00
Price Range $23.00 - $24.00
Offer Shares (mm) 23.5
Deal Size ($mm) $588
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/03/2021
Offer Price $25.00
Price Range $23.00 - $24.00
Offer Shares (mm) 23.5
Deal Size ($mm) $588
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Seattle, WA
Founded 2018
Employees 240
Website www.sana.com